Chapman PB - Search Results

1

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Ku GY, et al. Among authors: chapman pb. Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951. Cancer. 2010. PMID: 20143434 Free PMC article.

2

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.

Steffens TA, Bajorin DF, Chapman PB, Lovett DR, Cody-Johnson BV, Templeton MA, Heelan RT, Wong GY, Portlock CS, Oettgen HF, et al. Steffens TA, et al. Among authors: chapman pb. Cancer. 1991 Sep 15;68(6):1230-7. doi: 10.1002/1097-0142(19910915)68:6<1230::aid-cncr2820680608>3.0.co;2-q. Cancer. 1991. PMID: 1873774 Clinical Trial.

3

Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.

Chapman PB, Lonberg M, Houghton AN. Chapman PB, et al. Cancer Res. 1990 Mar 1;50(5):1503-9. Cancer Res. 1990. PMID: 2105840

4

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, et al. Bajorin DF, et al. Among authors: chapman pb. Cancer Res. 1990 Dec 1;50(23):7490-5. Cancer Res. 1990. PMID: 2253196 Clinical Trial.

5

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Chapman PB, Gillies SD, Houghton AN, Reilly RM. Chapman PB, et al. Cancer Immunol Immunother. 1994 Sep;39(3):198-204. doi: 10.1007/BF01533387. Cancer Immunol Immunother. 1994. PMID: 7522964 Free PMC article.

6

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.

Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. Minasian LM, et al. Among authors: chapman pb. Cancer. 1995 May 1;75(9):2251-7. doi: 10.1002/1097-0142(19950501)75:9<2251::aid-cncr2820750910>3.0.co;2-f. Cancer. 1995. PMID: 7536122 Clinical Trial.

7

Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.

Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Hara I, et al. Among authors: chapman pb. Int J Cancer. 1995 Apr 10;61(2):253-60. doi: 10.1002/ijc.2910610219. Int J Cancer. 1995. PMID: 7705956

8

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.

Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Sirott MN, et al. Among authors: chapman pb. Cancer. 1993 Nov 15;72(10):3091-8. doi: 10.1002/1097-0142(19931115)72:10<3091::aid-cncr2820721034>3.0.co;2-v. Cancer. 1993. PMID: 8221576

9

Anti-idiotypic monoclonal antibody cancer vaccines.

Chapman PB. Chapman PB. Semin Cancer Biol. 1995 Dec;6(6):367-74. doi: 10.1016/1044-579x(95)90006-3. Semin Cancer Biol. 1995. PMID: 8938275 Review.

10

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Nasi ML, et al. Among authors: chapman pb. Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Melanoma Res. 1997. PMID: 9578432 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters